Do NOT Use Colchicine in Post-Infarction Pericarditis
Colchicine should be avoided in patients with post-myocardial infarction pericarditis (epistenocardiac pericarditis) due to the risk of myocardial rupture and lack of proven benefit in this specific population.
Critical Distinction: Post-MI Pericarditis vs. Idiopathic Pericarditis
The ESC guidelines 1 provide Class I, Level A recommendations for colchicine in acute idiopathic or viral pericarditis, but these guidelines do not address post-infarction pericarditis as a separate entity. This is a crucial gap that must inform clinical decision-making.
Why This Patient is Different
Post-infarction pericarditis occurs in the context of:
- Healing myocardial tissue with compromised structural integrity
- Active inflammatory response that is part of normal wound healing
- Risk of mechanical complications including myocardial rupture
The anti-inflammatory effects of colchicine that benefit idiopathic pericarditis may actually impair myocardial healing in the post-MI setting.
Evidence Against Colchicine Use
Recent case reports document colchicine-induced myocardial rupture 2. A 2024 case described suspected colchicine-induced late myocardial rupture occurring three weeks post-inferior STEMI while the patient was on colchicine therapy. This raises serious concerns about colchicine's anti-healing effects on infarcted myocardium.
Large-scale RCT data show no benefit post-MI 3. The 2025 CLEAR trial randomized 7,062 patients with myocardial infarction to colchicine versus placebo over a median 3-year follow-up. The primary composite outcome (CV death, recurrent MI, stroke, or unplanned revascularization) occurred in 9.1% with colchicine versus 9.3% with placebo (HR 0.99,95% CI 0.85-1.16, P=0.93). Colchicine provided no cardiovascular benefit but increased diarrhea (10.2% vs 6.6%, P<0.001).
Meta-analyses confirm lack of efficacy 4, 5. A 2025 meta-analysis of 14 RCTs with 14,326 patients found colchicine post-MI did not reduce adverse CV events, mortality, recurrent MI, repeat revascularization, post-MI heart failure, or stroke. However, it significantly increased gastrointestinal adverse events (RR 1.74,95% CI 1.20-2.51).
Recommended Treatment Approach
Use high-dose aspirin as first-line therapy 6, 7:
- Aspirin 750-1000 mg every 8 hours
- Already indicated for post-MI antiplatelet therapy
- Provides anti-inflammatory effect without impairing myocardial healing
- Continue for 1-2 weeks with gradual taper
Add gastroprotection with proton pump inhibitor given high-dose aspirin use.
Monitor treatment response with:
- Serial C-reactive protein levels
- Clinical symptom resolution
- Echocardiographic assessment of effusion size
Important Caveats
If aspirin is contraindicated or not tolerated, consider:
- Ibuprofen 600 mg every 8 hours as alternative NSAID
- Low-dose corticosteroids (prednisone 0.2-0.5 mg/kg/day) only if NSAIDs cannot be used and infectious causes excluded
- Avoid corticosteroids if possible as they promote chronicity and recurrence
Avoid colchicine specifically in:
- Post-MI pericarditis (epistenocardiac pericarditis)
- Large infarct size with extensive myocardial injury
- Late presentation MI where healing is ongoing
The evidence for colchicine efficacy exists only for idiopathic/viral pericarditis 8, 9, not post-infarction pericarditis. The pathophysiology differs fundamentally—post-MI pericarditis represents localized inflammation over healing myocardium where anti-inflammatory therapy may impair necessary healing processes.